Currently Viewing:
American Heart Association Scientific Sessions 2019
Currently Reading
Kiersten Combs Discusses Findings of the DAPA-HF Study in Population Without Diabetes
November 17, 2019
Details of DAPA-HF Results Point to Dapagliflozin for Some Heart Failure Patients Without Diabetes
November 17, 2019
In Stable Heart Disease, Study Finds Stents Might Be No Better Than Drugs
November 17, 2019
Dapagliflozin Meets Quality-of-Life Marks, Efficacy Among Seniors, Data Show
November 17, 2019
From Self-Reporting Accuracy to Therapy Access: AHA Posters Cover Issues in Disparities
November 18, 2019
Dr John Pfeifer Outlines Necessary Steps for Preventive Action in Patients With Atrial Fibrillation
November 18, 2019
Sara Levintow Analyzes 2013 ACC/AHA Cholesterol Guidelines in Relation to Trends in US Lipid Testing
November 18, 2019
Plaques May Be Key to Vascepa's Role in Preventing CV Events
November 18, 2019
48-Week Results for Mavacamten Draw Crowd at AHA Session
November 19, 2019
Dr Vinay Kini Discusses the Growing Influence of the EHR in the Transition to Value-Based Care
November 19, 2019
Dr Stephen Heitner Details the Significance of the PIONEER-OLE Study in Treating Obstructive HCM
November 19, 2019
Dr Stephen Heitner Outlines the Next Steps After MAVERICK-HCM Study Findings
November 21, 2019
Dr Stephen Voyce Details Innovations and Preventive Strategies in Detection of Atrial Fibrillation
November 24, 2019
Dr Brent Williams Discusses Study Findings on Detection of Atrial Fibrillation
November 27, 2019
Dr Brandon Fornwalt Discusses the Preventive Efficacy of AI in Monitoring for Atrial Fibrillation
November 30, 2019
Dr Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD
December 04, 2019
Dr Brian Ghoshhajra Details the Significance of the PDS-2 System in Affecting Progression of HoFH
December 05, 2019
Dr Roland Chen Outlines the GUARD-AF Trial as a Preventive Mechanism in Reducing Risk of Stroke
December 06, 2019
Dr Darryl Sleep: Identifying and Treating Elevated LDL-C in Patients Can Mitigate Heart Attack Risk
December 06, 2019
Dr C. Noel Bairey Merz Discusses ESCaPE-CMD Phase 2 Study Results of Patients With CMD
January 03, 2020
Dr Javed Butler Discusses Why People With Diabetes Are at Greater Risk of Heart Failure
January 11, 2020
Dr Jay Edelberg Discusses PIONEER-OLE and Design of EXPLORER-HCM in Patients With Obstructive HCM
January 16, 2020
Dr Jay Edelberg Explains Preventive Efficacy and Potential FDA Approval of Mavacamten
January 26, 2020
Dr Roland Chen Discusses the Primary Endpoints of the GUARD-AF Trial for Atrial Fibrillation
January 31, 2020

Kiersten Combs Discusses Findings of the DAPA-HF Study in Population Without Diabetes

A compelling paradigm is forming in which dapagliflozin can be prescribed not only to prevent heart failure in people with type 2 diabetes, but also in the patients without diabetes, said Kiersten Combs, US vice president of Cardiovascular Metabolism at AstraZeneca.


A compelling paradigm is forming in which dapagliflozin can be prescribed not only to prevent heart failure in people with type 2 diabetes, but also in the patients without diabetes, said Kiersten Combs, US vice president of Cardiovascular Metabolism at AstraZeneca.

Transcript

The focus of the presentations at this year’s American Heart Association meeting is how dapagliflozin can offer protection against worsening of heart failure even in patients who do not have diabetes. The initial results released in Paris [at the European Society of Cardiology] showed that these benefits were nearly identical in patients with and without diabetes. How have payers responded to these data?

We’re extremely excited about our presence here across our cardiovascular metabolic portfolio, but specifically, to your point, the DAPA-HF data and some cut analysis that we’re reading out here is quite compelling. To your point, both in what you see in the heart failure composite endpoint, a 27% relative risk reduction in non-diabetic patients and a 25% relative risk reduction in the diabetic patient. From a payer perspective, since we introduced this data in Paris, we have taken it and talked to many of our payers, and just as the scientific community has been extremely excited about this data, we are seeing the same positive response from payers.

The recent study in JAMA Cardiology shows that heart failure is increasing in the US population. How can the findings from DAPA-HF translate into a broad-based solution for at-risk patients?

I think not only in heart failure patients, but also when you look at the data that’s in DECLARE [DECLARE-TIMI] that shows in type 2 diabetic patients that we can prevent the hospitalization of heart failure. When you put those together, there is a really compelling paradigm shifting science that suggests that as this goes through the regulatory process, we could be in a place where Farxiga [dapagliflozin] can not only prevent heart failure in type 2 diabetics, but then also treat both in the diabetic and non-diabetic patient population.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up